Young Company with Prospective Clinical Data

  • PCDx™ and Paradigm was developed from $27.36 M in grant funding to a non-profit entity beginning in August of 2012 by the University of Michigan Health System (UMHS) with support from the International Genomics Consortium (IGC).

  • In June 2016 Paradigm transitioned clinical operations from Michigan to IGC's headquarters in Phoenix and transitioned to a C-Corp.

  • In July 2016 an independent prospective validation published by Indiana University School of Medicine demonstrated that treating based on PCDx™ improves progression free survival in advanced treatment refractory patients.

  • In August 2016 the PCDx™ test was shifted to Illumina and multiplexed and lower variable costs while solving reimbursement with over $2,500 a case with minimal burden to patients in the US.

  • Paradigm continues to expand the volume of patients processed in their laboratory at the Phoenix Biosciences Center and is growing pharmaceutical, diagnostic, and oncology collaborations to positively impact patient care.

Treatment according to PCDx™ Improves Progression Free Survival

The independent prospective validation study from Radovich et al. (2016) had the following significant findings:

  • Patients treated with genomically guided therapy had a superior median PFS compared to those treated with non-genomically guided therapy (86 days vs. 49 days, p=0.005, H.R.=0.55, 95% C.I.:0.37- 0.84)

  • 43% of patients treated with Paradigm’s genomically directed therapy attained a progression free survival (PFS) ratio ≥1.3 versus 5% treated with non-genomically guided therapy (p<0.0001).


Figure 3a from Radovich et al. (2016) showing progression free survival benefit for PCDx
Figure 3b from Radovich et al. (2016) showing progression free survival benefit for PCDx

Source: Radovich, M., et al., Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget, (2016) 7(35), 56491–56500

Added highlights in this publication:

  • Certain molecular-based biomarker analyses (mainly mRNA analyses) are almost exclusively done by Paradigm. Competitors just focusing on Next-Generation Sequencing (NGS) or not performing mRNA analyses would have missed equal to 8/19 (42%) of patients.

PCDx™ Outperformes Competitors

The study from Weiss et al. (2015) showed that looking at typical clinical parameters, PCDx™ even in early days of preliminary launch outperformed a major competitor in terms of:

  • Indentifying clinically actionable therapeutic associtations

  • Turnaround Time (TAT).

Source: Weiss, G.J., et al., Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. Onco Targets Ther., (2015) 8, 959–967